Shionogi Still Hopeful For Xocova In US Despite Phase III Fail

Missed Primary Endpoints

 
• By Lisa Takagi
Shionogi's Xocova faced a thick wall of P3 failure before its NDA filing in the US after a huge commercial success in Japan.
Xocova faces US Phase Phase III failure after commercial success in Japan • Source: Shutterstock

More from Clinical Trials

More from R&D